Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Almirall ( (ES:ALM) ) is now available.
Almirall reported higher net sales in 2025, driven chiefly by strong performance of its European dermatology portfolio, notably Ebglyss, Ilumetri, and Wynzora, with Ebglyss expanding into major European markets. On the R&D front, the Anti-IL1RAP candidate for hidradenitis suppurativa progressed to Phase II, while the company reiterated its goal of running six proof-of-concept studies by the end of 2026.
The company fully applied the Remuneration Policy approved in 2024, and shareholder support for its 2024 remuneration report rose sharply, with 98.80% backing at the 2025 AGM. This strong endorsement underscores improved governance and transparency around directors’ pay, reinforcing Almirall’s commitment to aligning remuneration with performance and maintaining high standards in its engagement with investors.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a listed Spanish pharmaceutical company focused on medical dermatology, with a growing portfolio of prescription treatments for conditions such as atopic dermatitis and psoriasis. Its core European dermatology brands include Ebglyss, Ilumetri, and Wynzora, and it invests in early-stage R&D to expand its pipeline in inflammatory skin diseases.
Average Trading Volume: 200,021
Technical Sentiment Signal: Buy
Current Market Cap: €2.97B
For detailed information about ALM stock, go to TipRanks’ Stock Analysis page.